Investigational drug · Phase 2
HLX01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Membranous Nephropathy, Lupus Nephritis (LN).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "HLX01"
First trial start
2025
Aug 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Membranous Nephropathy
- Lupus Nephritis (LN)
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX01" as an intervention, largest first.
- Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCLPivotal-lookingCompleted
Shanghai Henlius BiotechIndustry
NCT02787239 · 407 participants · Start Oct 2015 · Primary completion May 2018
Drug: HLX01; Rituximab and 1 more · For: B-cell Non Hodgkin's Lymphoma
Sites: Beijing, China
- Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid ArthritisPivotal-lookingCompleted
Shanghai Henlius BiotechIndustry
NCT03522415 · 275 participants · Start May 28, 2018 · Primary completion Apr 5, 2020
Drug: HLX01; Methotrexate(MTX) · For: Moderately to Severely Active Rheumatoid Arthritis
Sites: Jiujiang, China
Shanghai Henlius BiotechIndustry
NCT03355872 · 194 participants · Start Feb 2016 · Primary completion Aug 2018
Drug: HLX01 · For: Rheumatoid Arthritis
- Rituximab and RASi in Patients with IgANPivotal-lookingCompleted
Nan Chen,MDAcademic, hospital or other
NCT04525729 · 116 participants · Start Jul 1, 2020 · Primary completion Mar 30, 2024
Drug: Rituximab; RAS 2410 · For: IgA Nephropathy
Sites: Shanghai, China
- Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT06251180 · 112 participants (planned) · Start Apr 10, 2024 · Primary completion Jun 30, 2027
Drug: Rocbrutinib; Rituximab and 4 more · For: B-cell Non-Hodgkin Lymphoma
Sites: Guangzhou, China
Shanghai Henlius BiotechIndustry
NCT02584920 · 87 participants · Start Oct 2014 · Primary completion Aug 2015
Drug: HLX01; Rituximab · For: B-cell Non Hodgkin's Lymphoma
Huiqiang HuangAcademic, hospital or other
NCT04246359 · 52 participants (planned) · Start Jan 15, 2020 · Primary completion Jun 16, 2022
Drug: Rituximab Biosimilar; Pegylated Interferon α-2b · For: Lymphoma, B-Cell
Sites: Guangzhou, China
Shanghai Henlius BiotechIndustry
NCT07038382 · 24 participants (planned) · Start Aug 5, 2025 · Primary completion Jan 2027
Drug: HLX79 10mg/kg/Placebo+HLX01; HLX79 20mg/kg/Placebo + HLX01 and 1 more · For: Membranous Nephropathy; Lupus Nephritis (LN)
Sites: Beijing, China; Changsha, China; Guangzhou, China · 17 sites in all
Shanghai Henlius BiotechIndustry
NCT03218072 · 12 participants · Start May 4, 2014 · Primary completion Jan 31, 2015
Drug: HLX01 · For: B-cell Lymphomas
- Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab TreatmentPivotal-lookingWithdrawn
Children's Hospital of Fudan UniversityAcademic, hospital or other
NCT04531865 · 0 participants · Start Jan 1, 2021 · Primary completion Sep 1, 2022
Drug: Rituximab; Mycophenolate Mofetil and 1 more · For: Frequently Relapsing Nephrotic Syndrome; Steroid-Dependent Nephrotic Syndrome
Sites: Shanghai, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy.
Zou YZ, Du XL, Wang SH, et al. · BMC Pharmacol Toxicol 2026
- Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience.
Deng W, Yang S, Yang C, et al. · J Oncol Pharm Pract 2026
- Cost-effectiveness of HLX01 (Hanlikang®) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model analysis.
Wang C, Huang Y, Rao L, et al. · Front Pharmacol 2025
- Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Qin Y, Song Y, Wang D, et al. · BMC Cancer 2024
- Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.
Zeng X, Liu J, Liu X, et al. · Arthritis Res Ther 2022
- Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma.
Shi Y, Zhang Q, Han X, et al. · Chin J Cancer Res 2021
Also in development for Membranous Nephropathy
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- HLX79Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.